Fetuin A in Hashimoto Thyroiditis

Hashimoto Thyroiditis Clinical Trial

Official title:

Fetuin A as a New Marker of Inflammation in Hashimoto Thyroiditis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01884649
• Other study ID #: GEAH-1
• Status: Completed
• Phase: N/A
• First received: June 17, 2013
• Last updated: June 21, 2013
• Start date: May 2012
• Est. completion date: October 2012

Study information

• Verified date: June 2013
• Source: Istanbul Medeniyet University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Turkey: Ethics Committee
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Fetuin-A levels are reported to be low as a negative acute phase reactant in systemical inflammatory situations. Hashimoto thyroiditis is characterized with inflammation. In this study, we hypothesised that the serum fetuin A levels could be found to be low due to inflammation in patients with Hashimoto thyroiditis

Description:

Patients ≥ 20 years of age being followed up at the outpatient clinics of the Internal Medicine Department in Medeniyet University Goztepe Training and Research Hospital and fulfilling the eligibility criteria will be included in the study. Approval of the local ethics committee and informed consent of the participants will be received for the study. The study is conducted in accordance with the Declaration of Helsinki. Demographic characteristics, concomitant diseases, smoking and alcohol drinking habits, concomitant medication usage, anthropometric and biochemistry data of the eligible patients will be recorded. Patient group will consist of patients with newly diagnosed Hashimoto thyroiditis and the control group will consist of healthy volunteers.

Groups will be compared according to their demographic, an¬thropometric and biochemistry data and serum fetuin-A levels. In order to detect the relationship between the serum fetuin-A levels and clinical features, correlation analyses will be done.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 97
• Est. completion date: October 2012
• Est. primary completion date: October 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• patients newly diagnosed with Hashimoto thyroiditis

Exclusion Criteria:

• Acute infection

• Acute or chronic inflammatory disease

• Anti-inflammatory treatment (non-steroidal anti-inflammatory, corticosteroids etc.)

• Hypoxic situations (chronic obstructive pulmonary disease etc.)

• Severe heart, kidney and liver disease

• Pregnancy

• Endocrine disorders

• Malignancy

• Usage of drug that affects thyroid hormone levels

Study Design

Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Hashimoto Disease
• Hashimoto Thyroiditis
• Thyroiditis

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Istanbul Medeniyet University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparison of serum fetuin A levels between patients with Hashimoto thyroiditis and healthy subjects		1 day (The blood samples were obtained on the same day participants arrived to outpatient clinics.)	No